Tectochrysin Attenuates the Chemoresistance of Hepatocellular Carcinoma Cells to Sorafenib by Inhibiting the PI3K/AKT Signaling Pathway and ABCG2 Expression
Molecular Biotechnology · 14.08.2026
DOI: 10.1007/s12033-026-01588-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biotechnology, online erschienen am 14.08.2026. Verfasst von Hanqing Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China. huhanq80@hotmail.com. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China. huhanq80@hotmail.com.
- Institute of Hepatobiliary and Pancreatic Surgery, China Three Gorges University, Yichang, 443003, Hubei, China. huhanq80@hotmail.com.
- Yichang Central People's Hospital, Yichang, 443003, China. huhanq80@hotmail.com.
- The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China.
- Institute of Hepatobiliary and Pancreatic Surgery, China Three Gorges University, Yichang, 443003, Hubei, China.
- Yichang Central People's Hospital, Yichang, 443003, China.
Zitieren
APA
Hu, H., Zheng, X., Tian, G., Lu, L., & Xing, R. (2026). Tectochrysin Attenuates the Chemoresistance of Hepatocellular Carcinoma Cells to Sorafenib by Inhibiting the PI3K/AKT Signaling Pathway and ABCG2 Expression. Molecular Biotechnology. https://doi.org/10.1007/s12033-026-01588-9
Vancouver
Hu H, Zheng X, Tian G, Lu L, Xing R. Tectochrysin Attenuates the Chemoresistance of Hepatocellular Carcinoma Cells to Sorafenib by Inhibiting the PI3K/AKT Signaling Pathway and ABCG2 Expression. Molecular Biotechnology. 2026. doi:10.1007/s12033-026-01588-9
BibTeX
@article{Hu2026,
author = {Hu, Hanqing and Zheng, Xin and Tian, Guodong and Lu, Ling and Xing, Rongchun},
title = {Tectochrysin Attenuates the Chemoresistance of Hepatocellular Carcinoma Cells to Sorafenib by Inhibiting the PI3K/AKT Signaling Pathway and ABCG2 Expression},
journal = {Molecular Biotechnology},
year = {2026},
doi = {10.1007/s12033-026-01588-9}
}
EUVIMED